Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- SJR +1.8%, MON +1%, PKE +0.5%
M&A news:
- AMCN +23.9% (enters into Amendment No. 3 to the Agreement and Plan of Merger, extends the Termination Date to July 31, 2017 'so as to give the Special Committee sufficient time to consider the Revised Proposal')
- SPNC +26.3% (to be acquired by Philips (PHG) for $38.50 per share)
Other news:
- NVIV +14.5% (announced that two patients in the INSPIRE study of the Neuro-Spinal Scaffold have improved from sensory incomplete AIS B spinal cord injury to motor incomplete AIS C SCI in their most recent INSPIRE assessments)
- ALQA +14.3% (indicated higher after Celgene affirms increased active stake to 18.8% pursuant to June 23 securities purchase agreement)
- NTNX +8.2% (signed partnership with Google )
- CRNT +5.2% (Q2 orders update)
- CBIO +4.3% ( granted orphan medicinal product designation by the European Commission for CB 2679d/ISU304)
- SGBX +3.3% (signs an agreement with One Earth Recycling)
Analyst comments:
- CY +3.9% (upgraded to Overweight from Equal Weight at Barclays)
- HUM +2% (initiated with a Buy at Citigroup)
- DLTR +1.8% (upgraded to Buy from Hold at Loop Capital)
- NVDA +1.5% (target raised to $170 from $145 at Susquehanna)
- EXPE +1.4% (upgraded to Buy from Neutral at Citigroup)
- GM +0.8% (resumed with a Overweight at Morgan Stanley)